Inhibikase Therapeutics (IKT) EBIT (2020 - 2024)
Historic EBIT for Inhibikase Therapeutics (IKT) over the last 5 years, with Q4 2024 value amounting to -$12.9 million.
- Inhibikase Therapeutics' EBIT fell 19359.61% to -$12.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$28.6 million, marking a year-over-year decrease of 4230.65%. This contributed to the annual value of -$28.6 million for FY2024, which is 4230.64% down from last year.
- According to the latest figures from Q4 2024, Inhibikase Therapeutics' EBIT is -$12.9 million, which was down 19359.61% from -$5.8 million recorded in Q3 2024.
- Over the past 5 years, Inhibikase Therapeutics' EBIT peaked at -$413921.0 during Q2 2020, and registered a low of -$12.9 million during Q4 2024.
- Over the past 5 years, Inhibikase Therapeutics' median EBIT value was -$4.6 million (recorded in 2022), while the average stood at -$4.2 million.
- Its EBIT has fluctuated over the past 5 years, first plummeted by 57364.46% in 2021, then surged by 1857.13% in 2024.
- Over the past 5 years, Inhibikase Therapeutics' EBIT (Quarter) stood at -$1.2 million in 2020, then crashed by 319.83% to -$5.0 million in 2021, then increased by 14.01% to -$4.3 million in 2022, then fell by 1.58% to -$4.4 million in 2023, then tumbled by 193.6% to -$12.9 million in 2024.
- Its EBIT stands at -$12.9 million for Q4 2024, versus -$5.8 million for Q3 2024 and -$5.1 million for Q2 2024.